Clinical and demographic data
| Total population | RR | SP+PP | |
|---|---|---|---|
| N (%) | 1615 | 315 (19.5) | 1035+261 (80.2) |
| Male (%) | 766 (47.4) | 147 (46.6) | 617 (47.6) |
| Female (%) | 849 (52.6) | 168 (53.3) | 679 (52.4) |
| Age (years, mean±SD) | 51±9.5 | 46.1±8.9 | 52±9.5* |
| Disease duration (years, mean±SD) | 17.5±8.6 | 13.4±7.6 | 18.4±8.6* |
| Baseline EDSS (median, range) | 6.5 (1.5–9.5) | 5.0±1.3 | 6.7±0.9* |
| NRS score T0, Baseline (n=1597 pts, mean±SD) | 7.5±1.4 | 7.4±1.5 | 7.6±1.4** |
| NRS score T1, month 1(n=1432 pts, mean±SD) | 5.9±1.6 | 5.5±1.8 | 5.9±1.6 |
| NRS T2, month 3 (n=889 pts, mean±SD) | 5.1±1.6 | 4.9±1.8 | 5.2±1.5 |
| NRS T3 month 6 (n=593 pts, mean±SD) | 4.8±1.7 | 4.7±1.9 | 4.9±1.6 |
| Dose, puffs number T1(mean±SD) | 6.8±2.6 | 6.2±2.9 | 6.8±2.6 |
| Dose, puffs number T2 (mean±SD) | 6.5±2.6 | 6.2±2.9 | 6.5±2.6 |
| Dose, puffs number T3 (mean±SD) | 6.3±2.8 | 6.3±3.1 | 6.2±2.7 |
*p<0.0001; **p=0.0251.
EDSS, expanding disability status scale; NRS, numerical rating scale; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.